Research
Size:
Share:

ONYX – Sponsored by Regeneron Pharmaceuticals, Inc.

Completed Study | Duration: 36 weeks

ONYX REGN910-3 was a multi-center, prospective, and randomized Phase II clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the efficacy of intravitreal REGN910-3 at different doses vs. intravitreal Eylea® (aflibercept). REGN910-3 is a new anti-angiopoietin -2 antibody that is a co-formulation of REGN910 and aflibercept. Like VEGF, Angiopoietin-2 is a key growth factor in the formation of blood vessels. The trial was for patients with newly diagnosed wet AMD who had received no prior anti-VEGF treatment.

Participants were treated and followed for 36 weeks.

Return to Age-Related Macular Degeneration